Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This research is being done to develop new treatment for non-hodgkin's lymphoma in subjects
whose cancer has returned or resisted treatment with chemotherapy. The investigational drug
clofarabine is being used in this study. An investigational drug is one that has not been
approved by the United States Food and Drug Administration (FDA).